Phospholipid compositions

A pharmaceutical composition comprising a plurality of bioactive phospholipids derived from egg yolk and one or more pharmaceutically acceptable diluents, excipients, and/or carriers, wherein said plurality of phospholipids is enriched in one or more lipids selected from the group consisting of:

• (i) one or more phosphatidylethanolamine (PE) and/or phosphatidylcholine (PC) derivatives having the structure:
• where R1 or R2 are independently selected from the group consisting of hydrogen, palmitoyl (C16:0), hexadecenoyl (C16:1), palmitoleoyl (C16:1), stearoyl (C18:0), octadecenoyl (C18:1), oleoyl (C18:1), octadecadienoyl (C18:2), linoleoyl (C18:2), α-linolenoyl (C18:3), octadecatrienoyl (C18:3), arachidonoyl (C20:4), eicosatetraenoyl (C20:4), docosapentaenoyl (C22:5), and docosahexaenoyl (C22:6) radicals;
• R3 is selected from hydrogen, methyl, or a C2-C18 acyl group;
• wherein if R3 is an acyl group then the R4 or R5 is absent and the nitrogen bonded to R3 is uncharged;
• R4 and R5 are independently selected from the group consisting of hydrogen or methyl, or pharmaceutically acceptable salts thereof;
• and/or
• (ii) one or more sphingomyelin (SPH) derivatives having the structure
• wherein R6 is palmitoyl (C16:0), stearoyl (C18:0), oleoyl (C18:1), tetradecanoyl (C14:0), heptadecanoyl (C17:0), nonadecanoyl (C19:0), eicosanoyl (C20:0), docosanoyl (C22:0), docosenoyl (C22:1), henicosanoyl (C23:0), tetracosadienoic (C24:2), or tetracosanoyl (C14:0);
• and pharmaceutically acceptable salts thereof.